Reported 1 day ago
Last week, Hims & Hers Health, Inc. (NYSE:HIMS) saw its stock price jump by 45.3% to $40.82, largely due to the announcement of a long-term partnership with Novo Nordisk involving the marketing of their weight loss drug, Wegovy. This surge occurred in a generally positive market backdrop, following favorable corporate earnings and a pause in tariff disputes. Investors are now keenly awaiting the company's upcoming earnings announcement on May 5, 2025.
Source: YAHOO